Amicus Therapeutics Inc (FOLD NASDAQ) stock market data APIs
$6.121
0.12(2%)
as of July 11, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
6.121
Open
6.2401
High
6.2401
Low
6.0379
52 wk Range
5.51-12.65
Market Cap
1 940 M
Shares Outstanding
308 M
Revenue
543 M
EPS
0.03
Beta
0.525
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 543 M
- EBITDA: 56 018 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDA...
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 25, Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced that Japan’s Minis...
High Growth Tech Stocks In The US To Watch This July 2025
The United States market has experienced a 2.1% increase over the past week and is up 14% over the last year, with earnings projected to grow by 15% annually. In this environment, identifying high gro...
Amicus Therapeutics stock hits 52-week low at $5.55
Amicus Therapeutics (NASDAQ:FOLD) stock recently reached a 52-week low, touching $5.55, with InvestingPro data showing the stock is currently trading at $5.59, slightly above its 52-week low. Despite...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
